Local view for "http://purl.org/linkedpolitics/eu/plenary/2007-04-23-Speech-1-100"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech⁶
dcterms:Date	"2007-04-23"^^xsd:date⁶
dcterms:Is Part Of	lp_eu:Medicamentele pentru terapie avansată (dezbatere)⁶
dcterms:Language	"en"^^xsd:language⁶
lpv:document identification number	"en.20070423.17.1-100"⁶
lpv:hasSubsequent	lp_eu:2007-04-23-Speech-1-101⁶
lpv:speaker	lp:Giles Chichester⁶
lpv:spoken text	". Mr President, Commissioner, first of all I should like to thank the Commissioner for his remarks about this proposal and report. I warmly support them. I should also like to state quite clearly that my committee, the Committee on Industry, Research and Energy, supports this proposal and hopes that it will go forward smoothly. So we share that objective. Next I would like to remind colleagues that the interest groups – the patient groups who are most likely to be affected by this measure and to benefit from it – strongly support the measure. I regularly see reports in the press of exciting new therapies and developments in this field, but usually they are in the USA and not in Europe, which is to our loss. I would like to congratulate the rapporteur for his work, but I have to respectfully disagree with him with regard to the two amendments from the Committee on Legal Affairs which seemed to me, and to many on my committee, to be pushing in exactly the opposite, retrogressive direction to that of this proposal. So I join in supporting the compromise package which has been put forward, particularly by my distinguished colleague Mrs Roth-Behrendt, not least because independent observers tell me that this package is in line with the ITRE Committee’s position. So naturally I support it. I am speaking for the committee, Madam; I am speaking in my turn, and you should wait for yours. I would like to remind everybody that the world around us is changing technologically, socially (although manners may not be changing), scientifically, and, as we can see in this report, biomedically. We must not deny the patients of the future the therapies of tomorrow."@en⁴
lpv:spokenAs	substitute; Delegation for relations with the United States (2007-03-14--2009-07-13)²³ substitute; IMCO (2007-01-31--2009-07-13)²³ member; ITRE (2007-01-31--2009-07-13)²³ member; Conference of Delegation Chairs (2007-02-15--2008-03-26)²³ member_of_the_bureau; EPP-ED (2004-08-31--2009-07-13)²³ unknown; Conservative and Unionist Party (2004-07-20--2009-07-13)²³ substitute; Committee of Inquiry into the crisis of the Equitable Life Assurance Society (2007-02-09--2007-06-19)²³ chair; Delegation for relations with Australia and New Zealand (2007-03-14--2008-03-26)²³
lpv:translated text	"Mr President, Commissioner, first of all I should like to thank the Commissioner for his remarks about this proposal and report. I warmly support them. I should also like to state quite clearly that my committee, the Committee on Industry, Research and Energy, supports this proposal and hopes that it will go forward smoothly. So we share that objective. Next I would like to remind colleagues that the interest groups – the patient groups who are most likely to be affected by this measure and to benefit from it – strongly support the measure. I regularly see reports in the press of exciting new therapies and developments in this field, but usually they are in the USA and not in Europe, which is to our loss. I would like to congratulate the rapporteur for his work, but I have to respectfully disagree with him with regard to the two amendments from the Committee on Legal Affairs which seemed to me, and to many on my committee, to be pushing in exactly the opposite, retrogressive direction to that of this proposal. So I join in supporting the compromise package which has been put forward, particularly by my distinguished colleague Mrs Roth-Behrendt, not least because independent observers tell me that this package is in line with the ITRE Committee’s position. So naturally I support it. I am speaking for the committee, Madam; I am speaking in my turn, and you should wait for yours. I would like to remind everybody that the world around us is changing technologically, socially (although manners may not be changing), scientifically, and, as we can see in this report, biomedically. We must not deny the patients of the future the therapies of tomorrow."@cs¹ "Hr. formand, hr. kommissær! For det første vil jeg gerne takke kommissæren for hans bemærkninger vedrørende forslaget og betænkningen. Jeg støtter disse varmt. Jeg vil også gerne gøre det helt klart, at mit udvalg, Udvalget om Industri, Forskning og Energi, støtter dette forslag og håber, at det vil blive vedtaget uden hindringer. Vi er således enige om denne målsætning. Jeg vil desuden gøre kollegerne opmærksom på, at interessegrupperne - de patientgrupper, der med størst sandsynlighed vil blive berørt af denne foranstaltning og drage fordel heraf - bakker fuldt ud op om foranstaltningen. Jeg støder jævnligt på artikler i pressen om spændende nye behandlingsformer og udviklingstendenser på dette område, men det foregår i USA og ikke i Europa, hvilket er vores tab. Jeg vil gerne lykønske ordføreren med betænkningen, men jeg tillader mig at være uenig med ham om de to ændringsforslag fra Retsudvalget, idet jeg og mange af medlemmerne i mit udvalg mener, at de er et tilbageskridt, der går fuldstændig imod forslaget. Jeg støtter således også kompromispakken, der navnlig er blevet fremlagt af min ærede kollega fru Roth-Behrendt, ikke mindst fordi denne pakke ifølge uafhængige observatører er i overensstemmelse med ITRE-udvalgets holdning. Derfor støtter jeg naturligvis pakken. Jeg taler på vegne af udvalget. Jeg taler, når det er min tur, og De bør vente, til det er Deres tur. Jeg vil gerne gøre opmærksom på, at verden omkring os er i forandring både på det tekniske, sociale (selv om manererne måske ikke ændrer sig), videnskabelige, og som det fremgår af denne betænkning, biomedicinske område. Vi må ikke nægte fremtidens patienter morgendages behandlingsmetoder."@da² "Herr Präsident! Herr Kommissar! Zuallererst möchte ich dem Herrn Kommissar für seine Bemerkungen zu diesem Vorschlag und dem Bericht danken. Sie haben meine volle Unterstützung. Ich möchte ganz klar feststellen, dass mein Ausschuss, der Ausschuss für Industrie, Forschung und Energie, diesen Vorschlag unterstützt und hofft, dass er ohne Probleme angenommen wird. Wir haben also dort das gleiche Ziel. Außerdem möchte ich die Kolleginnen und Kollegen daran erinnern, dass die Interessengruppen – die Patientengruppen, die von dieser Verordnung höchstwahrscheinlich am stärksten betroffen sind und davon profitieren – diese Maßnahme einhellig unterstützen. In der Presse finde ich regelmäßig Berichte über fantastische neue Therapien und Entwicklungen auf diesem Gebiet, doch in der Regel geht es um die USA und nicht um Europa, was schlecht für uns ist. Ich möchte dem Berichterstatter zu seiner Arbeit gratulieren, möchte jedoch respektvoll erklären, dass ich in Bezug auf die beiden Änderungsanträge vom Rechtsausschuss anderer Meinung bin. Nach meinem Dafürhalten und dem vieler Mitglieder meines Ausschusses scheinen sie in eine genau entgegengesetzte, rückschrittliche Richtung entgegen diesem Vorschlag zu gehen. Daher schließe ich mich den Befürwortern des Kompromisspakets an, das insbesondere von meiner verehrten Kollegin, Frau Roth-Behrendt, vorgelegt wurde, nicht zuletzt deshalb, weil mir unabhängige Beobachter sagen, dass dieses Paket mit dem Standpunkt des Ausschusses für Industrie, Forschung und Energie in Einklang steht. Also unterstütze ich es natürlich. Ich spreche für den Ausschuss, Frau Kollegin. Jetzt bin ich dran, und Sie sollten warten, bis Sie an der Reihe sind. Ich möchte alle daran erinnern, dass sich die Welt um uns herum in technologischer, sozialer (obwohl sich möglicherweise Verhaltensweisen nicht ändern), wissenschaftlicher und – wie wir aus diesem Bericht ersehen können – biomedizinischer Hinsicht verändert. Wir dürfen den Patienten der Zukunft die Therapien von morgen nicht verwehren."@de⁹ "Κύριε Πρόεδρε, κύριε Επίτροπε, καταρχάς θέλω να ευχαριστήσω τον Επίτροπο για τις παρατηρήσεις του σχετικά με την υπό συζήτηση πρόταση και την έκθεση. Τις χαιρετίζω θερμά. Θέλω επίσης να δηλώσω απερίφραστα ότι η επιτροπή μου, η Επιτροπή Βιομηχανίας, Έρευνας και Ενέργειας, στηρίζει αυτήν την πρόταση και ευελπιστεί ότι θα προχωρήσει ομαλά. Συνεπώς, συμμεριζόμαστε αυτόν τον στόχο. Εν συνεχεία, θέλω να υπενθυμίσω στους συναδέλφους ότι οι ομάδες πίεσης –οι ομάδες ασθενών που πρόκειται να επηρεαστούν πιθανότερα από το εν λόγω μέτρο και να επωφεληθούν από αυτό– υποστηρίζουν θερμά το μέτρο. Βλέπω συχνά αναφορές στον Τύπο για εντυπωσιακές νέες θεραπείες και εξελίξεις σε αυτόν τον τομέα, αλλά συνήθως εμφανίζονται στις ΗΠΑ και όχι στην Ευρώπη, πράγμα το οποίο αποβαίνει εις βάρος μας. Οφείλω να συγχαρώ τον εισηγητή για το έργο του, αλλά είμαι υποχρεωμένος να διαφωνήσω μαζί του όσον αφορά τις δύο τροπολογίες της Επιτροπής Νομικών Θεμάτων οι οποίες, κατά τη γνώμη μου, και κατά τη γνώμη πολλών μελών της επιτροπής μου, ωθούν ακριβώς στην αντίθετη, ανάδρομη κατεύθυνση της οδηγίας. Υποστηρίζω, λοιπόν, τη συμβιβαστική δέσμη που έχει υποβληθεί, συγκεκριμένα, από τη διακεκριμένη συνάδελφό μου κ. Roth-Behrendt, αν μη τι άλλο επειδή ανεξάρτητοι παρατηρητές με πληροφορούν ότι η εν λόγω συμβιβαστική δέσμη συνάδει με τη θέση της Επιτροπής Βιομηχανίας. Συνεπώς, φυσικά την υποστηρίζω. Μιλώ εξ ονόματος της επιτροπής, κυρία μου· μιλώ στη σειρά μου, και εσείς πρέπει να περιμένετε τη δική σας. Θέλω να υπενθυμίσω σε όλους ότι ο κόσμος γύρω μας αλλάζει τεχνολογικά, κοινωνικά (παρότι ενδεχομένως οι τρόποι δεν αλλάζουν), επιστημονικά και, όπως μπορούμε να δούμε σε αυτήν την έκθεση, βιοϊατρικά. Δεν πρέπει να αρνούμαστε στους μελλοντικούς ασθενείς τις θεραπείες του αύριο."@el¹⁰ ". Señor Presidente, señor Comisario, en primer lugar me gustaría dar las gracias al Comisario por sus observaciones sobre esta propuesta y el informe. Las apoyo de todo corazón. También me gustaría dejar muy claro que mi comisión, la Comisión de Industria, Investigación y Energía, apoya esta propuesta y espera que sea aprobada sin problemas. Así pues, compartimos ese objetivo. También me gustaría recordar a mis colegas que los grupos de interés –los grupos de pacientes que más probabilidades tienen de verse afectados por esta medida y de beneficiarse de ella– también la apoyan con firmeza. A menudo veo publicaciones en la prensa sobre nuevas terapias y avances interesantes en este campo, pero normalmente se producen en los Estados Unidos y no en Europa, lo que nos perjudica. Me gustaría felicitar al ponente por su trabajo, pero, con todos mis respetos, no estoy de acuerdo con él en relación con las dos enmiendas de la Comisión de Asuntos Jurídicos, que me parecen a mí y a muchos miembros de mi comisión, que van en la dirección contraria a la de esta propuesta y suponen un paso atrás. Por tanto, apoyo el paquete de compromiso que se ha presentado, en particular por mi distinguida colega la señora Roth-Behrendt, entre otras cosas porque observadores independientes me dicen que este paquete coincide con la posición de la Comisión de Industria, Investigación y Energía. Así que lo apoyo, por supuesto. Hablo en nombre de la comisión, señora; hablo en mi turno y usted debería esperar al suyo. Me gustaría recordar a todos y a todas que el mundo que nos rodea está cambiando desde el punto de vista tecnológico, social (aunque puede que los modales no cambien), científico y, como podemos ver en este informe, biomédico. No debemos negar a los pacientes del futuro las terapias del mañana."@es²¹ "Mr President, Commissioner, first of all I should like to thank the Commissioner for his remarks about this proposal and report. I warmly support them. I should also like to state quite clearly that my committee, the Committee on Industry, Research and Energy, supports this proposal and hopes that it will go forward smoothly. So we share that objective. Next I would like to remind colleagues that the interest groups – the patient groups who are most likely to be affected by this measure and to benefit from it – strongly support the measure. I regularly see reports in the press of exciting new therapies and developments in this field, but usually they are in the USA and not in Europe, which is to our loss. I would like to congratulate the rapporteur for his work, but I have to respectfully disagree with him with regard to the two amendments from the Committee on Legal Affairs which seemed to me, and to many on my committee, to be pushing in exactly the opposite, retrogressive direction to that of this proposal. So I join in supporting the compromise package which has been put forward, particularly by my distinguished colleague Mrs Roth-Behrendt, not least because independent observers tell me that this package is in line with the ITRE Committee’s position. So naturally I support it. I am speaking for the committee, Madam; I am speaking in my turn, and you should wait for yours. I would like to remind everybody that the world around us is changing technologically, socially (although manners may not be changing), scientifically, and, as we can see in this report, biomedically. We must not deny the patients of the future the therapies of tomorrow."@et⁵ ". Arvoisa puhemies, arvoisa komission varapuheenjohtaja, aivan ensimmäiseksi haluan kiittää komission varapuheenjohtajaa siitä, mitä hän totesi tästä ehdotuksesta ja mietinnöstä. Kannatan lämpimästi hänen huomioitaan. Lisäksi haluan todeta selkeästi, että oma valiokuntani, teollisuus-, tutkimus- ja energiavaliokunta, tukee tätä ehdotusta ja toivoo, että se etenee ongelmitta. Meillä on siis yhteinen tavoite. Seuraavaksi haluan muistuttaa kollegoja siitä, että sidosryhmät – potilasryhmät, joihin tämä toimi todennäköisimmin vaikuttaa ja jotka siitä todennäköisimmin hyötyvät – tukevat voimakkaasti tätä toimea. Olen nähnyt lehdistössä säännöllisesti artikkeleja kiinnostavista, uusista terapioista ja alan kehityksestä, mutta tavallisesti ne koskevat Yhdysvaltoja eivätkä EU:ta, mikä on meidän kannaltamme vahinko. Haluan kiittää esittelijää hänen tekemästään työstä, mutta minun on kaikella kunnioituksella oltava hänen kanssaan eri mieltä oikeudellisen valiokunnan esittämästä kahdesta tarkistuksesta, jotka näyttivät omasta mielestäni ja monien valiokuntani jäsenten mielestä vievän päinvastaiseen suuntaan ja taaksepäin ehdotukseen verrattuna. Niinpä yhdyn niihin, jotka kannattavat kompromissipakettia, jota on esittänyt erityisesti arvoisa kollegani jäsen Roth-Behrendt, varsinkin, kun riippumattomat tarkkailijat ovat kertoneet minulle, että tämä paketti on teollisuus-, ulkomaankauppa-, tutkimus- ja energiavaliokunnan kannan mukainen. Näin ollen on luonnollista, että tuen sitä. Arvoisa jäsen Breyer, puhun valiokunnan puolesta. Nyt on minun vuoroni puhua, ja teidän kuuluu odottaa omaa vuoroanne. Haluan muistuttaa kaikkia siitä, että maailma ympärillämme muuttuu teknologisesti, sosiaalisesti (vaikka tavat eivät ehkä muutukaan), tieteellisesti ja, kuten voimme nähdä tästä mietinnöstä, biolääketieteellisesti. Emme saa evätä tulevaisuuden potilailta huomisen terapioita."@fi⁷ ". Monsieur le Président, Monsieur le Commissaire, je voudrais tout d’abord remercier le commissaire pour ses remarques sur la proposition et sur le rapport à l’examen. Je les soutiens de tout cœur. Je voudrais également déclarer très clairement que ma commission, la commission de l’industrie, de la recherche et de l’énergie, soutient cette proposition et espère qu’elle suivra sa voie sans problème. Nous partageons donc cet objectif. Ensuite, je voudrais rappeler à mes collègues que les groupes d’intérêt - les associations de patients qui sont les plus susceptibles d’être concernés par cette mesure et d’en bénéficier - soutiennent fortement la mesure. Je lis régulièrement dans la presse des articles passionnants concernant de nouvelles thérapies et les évolutions dans ce domaine, mais, généralement, c’est aux États-Unis et non en Europe que cela se passe, ce qui est dommage pour nous. Je voudrais féliciter le rapporteur pour son travail, mais, avec tout le respect que je lui dois, je ne suis pas d’accord avec lui au sujet des deux amendements de la commission des affaires juridiques qui me semblent, à moi-même comme à de nombreux membres de ma commission, aller dans un sens exactement contraire et régressif par rapport à cette proposition. Alors je m’associe au soutien du paquet de compromis qui a été présenté en particulier par ma distinguée collègue Mme Roth-Behrendt, notamment parce que des observateurs indépendants me disent que ce paquet est conforme à la position de la commission ITRE. Donc, il va de soi que je le soutiens. Je parle au nom de la commission, Madame; j’ai pris la parole quand c’était mon tour et vous devriez attendre le vôtre. Je voudrais rappeler à tout un chacun que le monde autour de nous change au point de vue technologique, social (bien que les manières ne changent peut-être pas), scientifique et, comme nous pouvons le constater dans ce rapport, biomédical. Nous ne devons pas priver les patients de l’avenir des thérapies de demain."@fr⁸ "Mr President, Commissioner, first of all I should like to thank the Commissioner for his remarks about this proposal and report. I warmly support them. I should also like to state quite clearly that my committee, the Committee on Industry, Research and Energy, supports this proposal and hopes that it will go forward smoothly. So we share that objective. Next I would like to remind colleagues that the interest groups – the patient groups who are most likely to be affected by this measure and to benefit from it – strongly support the measure. I regularly see reports in the press of exciting new therapies and developments in this field, but usually they are in the USA and not in Europe, which is to our loss. I would like to congratulate the rapporteur for his work, but I have to respectfully disagree with him with regard to the two amendments from the Committee on Legal Affairs which seemed to me, and to many on my committee, to be pushing in exactly the opposite, retrogressive direction to that of this proposal. So I join in supporting the compromise package which has been put forward, particularly by my distinguished colleague Mrs Roth-Behrendt, not least because independent observers tell me that this package is in line with the ITRE Committee’s position. So naturally I support it. I am speaking for the committee, Madam; I am speaking in my turn, and you should wait for yours. I would like to remind everybody that the world around us is changing technologically, socially (although manners may not be changing), scientifically, and, as we can see in this report, biomedically. We must not deny the patients of the future the therapies of tomorrow."@hu¹¹ "Signor Presidente, signor Commissario, prima di tutto desidero ringraziare il Commissario per le sue osservazioni sulla proposta e sulla relazione, alle quali aderisco vivamente. Desidero inoltre precisare che la mia commissione, la commissione per l’industria, la ricerca e l’energia, sostiene la proposta e auspica che proceda in maniera fluida. Pertanto condividiamo questo obiettivo. Inoltre, desidero ricordare ai colleghi che i gruppi d’interesse – le associazioni di pazienti che con tutta probabilità sono i principali destinatari delle ricadute e dei benefici della normativa – sostengono fermamente il provvedimento. Leggo regolarmente di nuove esaltanti terapie e sviluppi in questo campo, ma di solito accade tutto negli Stati Uniti e non in Europa, il che va a nostro discapito. Porgo le congratulazioni al relatore per il lavoro svolto, ma dissento rispettosamente dalla sua posizione sui due emendamenti della commissione giuridica, che a me e a molti membri della mia commissione sono parsi esattamente agli antipodi, ovvero orientati in una direzione regressiva rispetto a quella della proposta. Pertanto mi associo al sostegno per il pacchetto di compromesso che è stato presentato, in particolare dall’esimia collega Roth-Behrendt, perché anche osservatori indipendenti mi hanno fatto presente che questo pacchetto è in linea con la posizione della commissione per l’industria, la ricerca e l’energia, e dunque sono ovviamente favorevole ad esso. Parlo a nome della commissione, signora; intervengo nello spazio che mi è stato concesso e lei dovrebbe attendere il suo turno. Desidero ricordare a tutti che il mondo che ci circonda sta cambiando molto a livello tecnologico, sociale (anche se forse le buone maniere non passeranno mai di moda), scientifico e, come possiamo vedere nella relazione, sul piano della biomedicina. Non dobbiamo quindi negare ai malati le terapie future di domani."@it¹² "Mr President, Commissioner, first of all I should like to thank the Commissioner for his remarks about this proposal and report. I warmly support them. I should also like to state quite clearly that my committee, the Committee on Industry, Research and Energy, supports this proposal and hopes that it will go forward smoothly. So we share that objective. Next I would like to remind colleagues that the interest groups – the patient groups who are most likely to be affected by this measure and to benefit from it – strongly support the measure. I regularly see reports in the press of exciting new therapies and developments in this field, but usually they are in the USA and not in Europe, which is to our loss. I would like to congratulate the rapporteur for his work, but I have to respectfully disagree with him with regard to the two amendments from the Committee on Legal Affairs which seemed to me, and to many on my committee, to be pushing in exactly the opposite, retrogressive direction to that of this proposal. So I join in supporting the compromise package which has been put forward, particularly by my distinguished colleague Mrs Roth-Behrendt, not least because independent observers tell me that this package is in line with the ITRE Committee’s position. So naturally I support it. I am speaking for the committee, Madam; I am speaking in my turn, and you should wait for yours. I would like to remind everybody that the world around us is changing technologically, socially (although manners may not be changing), scientifically, and, as we can see in this report, biomedically. We must not deny the patients of the future the therapies of tomorrow."@lt¹⁴ "Mr President, Commissioner, first of all I should like to thank the Commissioner for his remarks about this proposal and report. I warmly support them. I should also like to state quite clearly that my committee, the Committee on Industry, Research and Energy, supports this proposal and hopes that it will go forward smoothly. So we share that objective. Next I would like to remind colleagues that the interest groups – the patient groups who are most likely to be affected by this measure and to benefit from it – strongly support the measure. I regularly see reports in the press of exciting new therapies and developments in this field, but usually they are in the USA and not in Europe, which is to our loss. I would like to congratulate the rapporteur for his work, but I have to respectfully disagree with him with regard to the two amendments from the Committee on Legal Affairs which seemed to me, and to many on my committee, to be pushing in exactly the opposite, retrogressive direction to that of this proposal. So I join in supporting the compromise package which has been put forward, particularly by my distinguished colleague Mrs Roth-Behrendt, not least because independent observers tell me that this package is in line with the ITRE Committee’s position. So naturally I support it. I am speaking for the committee, Madam; I am speaking in my turn, and you should wait for yours. I would like to remind everybody that the world around us is changing technologically, socially (although manners may not be changing), scientifically, and, as we can see in this report, biomedically. We must not deny the patients of the future the therapies of tomorrow."@lv¹³ "Mr President, Commissioner, first of all I should like to thank the Commissioner for his remarks about this proposal and report. I warmly support them. I should also like to state quite clearly that my committee, the Committee on Industry, Research and Energy, supports this proposal and hopes that it will go forward smoothly. So we share that objective. Next I would like to remind colleagues that the interest groups – the patient groups who are most likely to be affected by this measure and to benefit from it – strongly support the measure. I regularly see reports in the press of exciting new therapies and developments in this field, but usually they are in the USA and not in Europe, which is to our loss. I would like to congratulate the rapporteur for his work, but I have to respectfully disagree with him with regard to the two amendments from the Committee on Legal Affairs which seemed to me, and to many on my committee, to be pushing in exactly the opposite, retrogressive direction to that of this proposal. So I join in supporting the compromise package which has been put forward, particularly by my distinguished colleague Mrs Roth-Behrendt, not least because independent observers tell me that this package is in line with the ITRE Committee’s position. So naturally I support it. I am speaking for the committee, Madam; I am speaking in my turn, and you should wait for yours. I would like to remind everybody that the world around us is changing technologically, socially (although manners may not be changing), scientifically, and, as we can see in this report, biomedically. We must not deny the patients of the future the therapies of tomorrow."@mt¹⁵ "Mijnheer de Voorzitter, commissaris, om te beginnen dank ik de commissaris voor zijn opmerkingen over dit voorstel en dit verslag. Ik steun ze van harte. Ik wil ook heel duidelijk aangeven dat mijn commissie, de Commissie industrie, onderzoek en energie, dit voorstel steunt en hoopt dat het zonder problemen zal worden aangenomen. Deze doelstelling delen we dus. Als volgende punt wijs ik mijn collega’s erop dat de belangengroepen – de patiëntengroepen die waarschijnlijk het meest met deze maatregel te maken zullen hebben en er profijt van kunnen trekken – volledig achter de maatregel staan. Ik zie regelmatig verslagen in de pers over spannende nieuwe therapieën en ontwikkelingen op dit gebied, maar helaas voor ons gaat het meestal over de VS en niet over Europa. Ik feliciteer de rapporteur met zijn werk, maar ik ben het, met alle respect, niet met hem eens als het gaat om de twee amendementen van de Commissie juridische zaken waarmee volgens mij, en vele anderen in mijn commissie, precies het tegenovergestelde wordt bereikt van wat met dit voorstel wordt beoogd. Ik steun dus het compromispakket dat, met name door mijn geachte collega mevrouw Roth-Behrendt, is voorgesteld, en dat doe ik niet in de laatste plaats omdat ik me door onafhankelijke waarnemers heb laten vertellen dat dit pakket aansluit bij het standpunt van de Commissie industrie, onderzoek en energie. Dus uiteraard steun ik het ook. Ik spreek namens de commissie, mevrouw. Ik ben nu aan de beurt om het woord te voeren; u moet op uw beurt wachten. Ik herinner iedereen eraan dat de wereld om ons heen verandert: op technologisch, wetenschappelijk en sociaal gebied (hoewel onze manieren misschien niet veranderen) en, zoals we in dit verslag kunnen zien, ook op biomedisch gebied. We moeten toekomstige patiënten niet de therapieën van morgen ontzeggen."@nl³ "Mr President, Commissioner, first of all I should like to thank the Commissioner for his remarks about this proposal and report. I warmly support them. I should also like to state quite clearly that my committee, the Committee on Industry, Research and Energy, supports this proposal and hopes that it will go forward smoothly. So we share that objective. Next I would like to remind colleagues that the interest groups – the patient groups who are most likely to be affected by this measure and to benefit from it – strongly support the measure. I regularly see reports in the press of exciting new therapies and developments in this field, but usually they are in the USA and not in Europe, which is to our loss. I would like to congratulate the rapporteur for his work, but I have to respectfully disagree with him with regard to the two amendments from the Committee on Legal Affairs which seemed to me, and to many on my committee, to be pushing in exactly the opposite, retrogressive direction to that of this proposal. So I join in supporting the compromise package which has been put forward, particularly by my distinguished colleague Mrs Roth-Behrendt, not least because independent observers tell me that this package is in line with the ITRE Committee’s position. So naturally I support it. I am speaking for the committee, Madam; I am speaking in my turn, and you should wait for yours. I would like to remind everybody that the world around us is changing technologically, socially (although manners may not be changing), scientifically, and, as we can see in this report, biomedically. We must not deny the patients of the future the therapies of tomorrow."@pl¹⁶ "Senhor Presidente, Senhor Comissário, antes de mais queria agradecer ao Senhor Comissário as considerações que teceu sobre a proposta e o relatório em apreço. Elas merecem um apoio caloroso da minha parte. Queria ainda afirmar de modo muito claro que a minha comissão, Comissão da Indústria, da Investigação e da Energia, apoia esta proposta e espera que o respectivo processo de adopção e aplicação decorra sem incidentes. Portanto, comungamos desse objectivo. Seguidamente, gostaria de recordar aos colegas que os grupos de interesses – as associações de doentes que deverão ser, em princípio, os mais afectados e beneficiados por esta medida – a apoiam vigorosamente. Vejo regularmente na imprensa notícias de novas terapias e desenvolvimentos empolgantes neste campo, mas em geral vêm dos EUA e não da Europa, para nossa desdita. Queria congratular o relator pelo seu trabalho, mas não posso deixar de discordar dele, com o devido respeito, quanto às duas alterações da Comissão dos Assuntos Jurídicos, que me pareceram, e a muita gente na minha comissão, visar objectivos retrógrados e diametralmente opostos aos da presente proposta. Assim, junto-me aos apoiantes do "pacote" de compromisso que foi apresentado, designadamente, pela minha distinta colega senhora deputada Roth-Behrendt, e isto nomeadamente pelo facto de, na avaliação de observadores independentes, estar em consonância com a posição da Comissão ITRE. Por isso tem, naturalmente, o meu apoio. Falo em nome da comissão, senhora deputada; é a minha vez de falar, e a senhora devia aguardar pela sua. Gostaria de recordar a todos que o mundo à nossa volta está em mudança tecnológica, social (ainda que as normas de boas maneiras possam não mudar), científica e, como se vê no presente relatório, biomédica. Não devemos negar aos doentes do futuro as terapias de amanhã."@pt¹⁷ "Mr President, Commissioner, first of all I should like to thank the Commissioner for his remarks about this proposal and report. I warmly support them. I should also like to state quite clearly that my committee, the Committee on Industry, Research and Energy, supports this proposal and hopes that it will go forward smoothly. So we share that objective. Next I would like to remind colleagues that the interest groups – the patient groups who are most likely to be affected by this measure and to benefit from it – strongly support the measure. I regularly see reports in the press of exciting new therapies and developments in this field, but usually they are in the USA and not in Europe, which is to our loss. I would like to congratulate the rapporteur for his work, but I have to respectfully disagree with him with regard to the two amendments from the Committee on Legal Affairs which seemed to me, and to many on my committee, to be pushing in exactly the opposite, retrogressive direction to that of this proposal. So I join in supporting the compromise package which has been put forward, particularly by my distinguished colleague Mrs Roth-Behrendt, not least because independent observers tell me that this package is in line with the ITRE Committee’s position. So naturally I support it. I am speaking for the committee, Madam; I am speaking in my turn, and you should wait for yours. I would like to remind everybody that the world around us is changing technologically, socially (although manners may not be changing), scientifically, and, as we can see in this report, biomedically. We must not deny the patients of the future the therapies of tomorrow."@ro¹⁸ "Mr President, Commissioner, first of all I should like to thank the Commissioner for his remarks about this proposal and report. I warmly support them. I should also like to state quite clearly that my committee, the Committee on Industry, Research and Energy, supports this proposal and hopes that it will go forward smoothly. So we share that objective. Next I would like to remind colleagues that the interest groups – the patient groups who are most likely to be affected by this measure and to benefit from it – strongly support the measure. I regularly see reports in the press of exciting new therapies and developments in this field, but usually they are in the USA and not in Europe, which is to our loss. I would like to congratulate the rapporteur for his work, but I have to respectfully disagree with him with regard to the two amendments from the Committee on Legal Affairs which seemed to me, and to many on my committee, to be pushing in exactly the opposite, retrogressive direction to that of this proposal. So I join in supporting the compromise package which has been put forward, particularly by my distinguished colleague Mrs Roth-Behrendt, not least because independent observers tell me that this package is in line with the ITRE Committee’s position. So naturally I support it. I am speaking for the committee, Madam; I am speaking in my turn, and you should wait for yours. I would like to remind everybody that the world around us is changing technologically, socially (although manners may not be changing), scientifically, and, as we can see in this report, biomedically. We must not deny the patients of the future the therapies of tomorrow."@sk¹⁹ "Mr President, Commissioner, first of all I should like to thank the Commissioner for his remarks about this proposal and report. I warmly support them. I should also like to state quite clearly that my committee, the Committee on Industry, Research and Energy, supports this proposal and hopes that it will go forward smoothly. So we share that objective. Next I would like to remind colleagues that the interest groups – the patient groups who are most likely to be affected by this measure and to benefit from it – strongly support the measure. I regularly see reports in the press of exciting new therapies and developments in this field, but usually they are in the USA and not in Europe, which is to our loss. I would like to congratulate the rapporteur for his work, but I have to respectfully disagree with him with regard to the two amendments from the Committee on Legal Affairs which seemed to me, and to many on my committee, to be pushing in exactly the opposite, retrogressive direction to that of this proposal. So I join in supporting the compromise package which has been put forward, particularly by my distinguished colleague Mrs Roth-Behrendt, not least because independent observers tell me that this package is in line with the ITRE Committee’s position. So naturally I support it. I am speaking for the committee, Madam; I am speaking in my turn, and you should wait for yours. I would like to remind everybody that the world around us is changing technologically, socially (although manners may not be changing), scientifically, and, as we can see in this report, biomedically. We must not deny the patients of the future the therapies of tomorrow."@sl²⁰ "Herr talman, herr kommissionsledamot! Låt mig först tacka kommissionsledamoten för hans synpunkter på förslaget och betänkandet. Jag instämmer till fullo. Jag vill också tydligt slå fast att mitt utskott, dvs. utskottet för industrifrågor, forskning och energi, stöder förslaget och hoppas att det antas utan problem. Vi delar alltså den målsättningen. Sedan vill jag påminna mina kolleger om att intressegrupperna, de patientgrupper som kommer att påverkas mest och gynnas av detta förslag, ger sitt fulla stöd. Jag läser ofta tidningsartiklar om nya intressanta behandlingar och framsteg inom detta område, men de sker oftast i USA och inte i Europa, vilket ligger oss i fatet. Jag vill gratulera föredraganden till hans arbete, men jag vill med all respekt säga att jag inte delar hans uppfattning om de båda ändringsförslagen från utskottet för rättsliga frågor. Jag och många andra i mitt utskott anser att de går stick i stäv mot förslagets i övrigt framåtsträvande ambition. Därför stöder jag det kompromisspaket som har lagts fram, i huvudsak av min ärade kollega Dagmar Roth-Behrendt, inte minst av den anledningen att oberoende observatörer anser att detta paket överensstämmer med industriutskottets ståndpunkt och därför stöder jag det naturligtvis. Jag talar för utskottet, fru Breyer. Jag talar nu när det är min tur, och ni borde vänta tills det blir er. Låt mig påminna alla om att vi lever i en föränderlig värld, både när det gäller teknik, samhälle (även om bristande uppförande kanske består), forskning och, som vi ser av detta betänkande, biomedicin. Vi får inte förvägra framtidens patienter tillgång till morgondagens terapier."@sv²²
lpv:unclassifiedMetadata	"(Afbrydelse fra fru Breyer: "Taler de på vegne af udvalget eller på egne vegne?")"² "(Einwurf von Frau Breyer: „Sprechen Sie für den Ausschuss oder in Ihrem eigenen Namen?“)"⁹ "(Inpass av Hiltrud Breyer: ”Talar ni för utskottets räkning eller för egen del?”)"²² "(Interjection from Mrs Breyer: ‘Are you speaking for the committee or on your own behalf?’)"^{18,5,20,15,1,19,14,16,11,13,4} "(Interpelação da deputada Breyer: "Está a falar em nome da comissão ou a título individual?")"¹⁷ "(Interpellation de Mme Breyer: «Parlez-vous au nom de la commission ou en votre propre nom?»)"⁸ "(Interrupción de la señora Breyer: «¿Está hablando en nombre de la comisión o en el suyo propio?»)"²¹ "(Interruptie van mevrouw Breyer: ‘Spreekt u nu namens de commissie of namens uzelf?)"³ "(Intromissione dell’onorevole Breyer: “Sta parlando a nome della commissione o espone la sua posizione personale?”)"¹² "(Jäsen Breyerin välihuomautus: "Puhutteko valiokunnan puolesta vai omasta puolestanne?")"⁷ "(Παρέμβαση από την κ. Breyer: «Μιλάτε εξ ονόματος της επιτροπής ή εξ ονόματος εσάς του ιδίου;»)"¹⁰ "Draftsman of the opinion of the Committee on Industry, Research and Energy"^{18,5,20,15,1,19,14,16,11,11,13} "Giles Chichester (PPE-DE ),"^{18,5,20,15,1,19,14,16,11,13,4} "draftsman of the opinion of the Committee on Industry, Research and Energy"⁴